Successful treatment of immunoblastic lymphadenopathy-like T-cell lymphomawith cyclosporin A

Immunoblastic lymphadenopathy (IBL)-like T-cell lymphoma is considered to b elong to peripheral T-cell lymphoma. Its prognosis is grave and effective t reatments have not been established, Recently, we gave oral cyclosporin A ( CsA) to a patient with IBL-like T-cell lymphoma, and succeeded in achieving dramatic remission. In this case, serum levels of interleukin-12 (IL-12) a nd tumor necrosis factor-alpha (TNF alpha) were elevated and decreased or r eturned to normal after achieving remission. Since CsA is a potent suppress or of the immune system and most notably T-cells, the immunosuppression of T-cell function might have played an important role in achieving remission in this case, although the precise mechanism still remains to be elucidated . The present case indicates that administration of CsA may be a very effec tive and safe selection of therapy for IBL-like T-cell lymphoma, as well as analogous disorders such as IBL and angioimmunoblastic lymphadenopathy wit h dysproteinemia (AILD), thereby will contribute to improving the prognosis of patients with these diseases.